Arcellx (ACLX) said Wednesday that a phase 2 study of anitocabtagene autoleucel showed that patients with relapsed or refractory multiple myeloma demonstrated an overall response rate of 97%.

The results also showed a complete response/stringent complete response rate of 68% and a very good partial response or higher rate of 85%, based on International Myeloma Working Group criteria as investigator-assessed, the company said.

Arcellx said no delayed or non-immune effector cell-associated neurotoxicity syndrome neurotoxicities have been observed to date with the therapy.

The company said it plans a commercial launch for the therapy in 2026.

Shares were up 6.2% in recent trading.

Price: 61.86, Change: +3.61, Percent Change: +6.20